Filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 10/31/2025
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2075 publications
Correction: Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma.
Journal: Blood cancer journal
Published: October 13, 2025
A plain language summary of the CEPHEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for people with newly diagnosed multiple myeloma who are not expected to receive a stem cell transplant.
Journal: Future oncology (London, England)
Published: October 08, 2025
Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX study.
Journal: Leukemia & lymphoma
Published: October 03, 2025
Treatment of transplant-ineligible newly diagnosed multiple myeloma: advances and future outlook
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Published: October 01, 2025
NK92 cells stably transfected with CD16 are efficient against multiple myeloma cells ex vivo and in vivo, especially if combined with daratumumab.
Journal: Oncoimmunology
Published: September 25, 2025
Acute interstitial pneumonitis associated with daratumumab treatment.
Journal: BMJ case reports
Published: September 22, 2025
Cost-per-responder analysis of daratumumab, bortezomib, lenalidomide, and dexamethasone vs bortezomib, lenalidomide, and dexamethasone among transplant-eligible patients with newly diagnosed multiple myeloma.
Journal: Journal of managed care & specialty pharmacy
Published: September 15, 2025
Mass Spectrometric Exploration of Biclonal Gammopathy: Insights from a Diagnostic Laboratory.
Journal: Journal of the American Society for Mass Spectrometry
Published: September 15, 2025
Comparison of utilization and total medicare fee-for-service expenditures for subcutaneous versus intravenous versions of a select group of therapies.
Journal: Journal of medical economics
Published: September 12, 2025
Treatment with Daratumumab for Immunotactoid Glomerulopathy Associated with Plasma Cell Dyscrasia: A Report of Two Cases.
Journal: Internal medicine (Tokyo, Japan)
Published: September 10, 2025
Evaluation of ambulatory use of daratumumab hyaluronidase injection.
Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: September 10, 2025
Last Updated: 10/31/2025